Suxia Luo

机构：Zhengzhou University, Henan Cancer Hospital, Dali University · ORCID：0000-0002-8639-7314

发表论文 127 篇 · 总被引 6937 次 · h-index 33

代表论文

• Pembrolizumab in HER2-Positive Gastric Cancer (2024 · New England Journal of Medicine · 被引 68)
• Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census (2024 · npj Precision Oncology · 被引 33)
• Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 16)
• Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial (2025 · Journal for ImmunoTherapy of Cancer · 被引 13)
• Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma (2024 · Clinical and Experimental Medicine · 被引 10)
• First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study (2025 · Advances in Therapy · 被引 9)